CN111689911A - 一种区域选择性合成7-芳硒基喹喔啉酮衍生物的方法 - Google Patents
一种区域选择性合成7-芳硒基喹喔啉酮衍生物的方法 Download PDFInfo
- Publication number
- CN111689911A CN111689911A CN202010575297.XA CN202010575297A CN111689911A CN 111689911 A CN111689911 A CN 111689911A CN 202010575297 A CN202010575297 A CN 202010575297A CN 111689911 A CN111689911 A CN 111689911A
- Authority
- CN
- China
- Prior art keywords
- arylselenoquinoxalinone
- derivatives
- derivative
- reaction
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 7
- 230000002194 synthesizing effect Effects 0.000 title claims description 4
- -1 diaryl diselenide Chemical compound 0.000 claims abstract description 33
- 238000006243 chemical reaction Methods 0.000 claims abstract description 31
- FFRYUAVNPBUEIC-UHFFFAOYSA-N quinoxalin-2-ol Chemical compound C1=CC=CC2=NC(O)=CN=C21 FFRYUAVNPBUEIC-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 11
- 239000007800 oxidant agent Substances 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 239000012363 selectfluor Substances 0.000 claims abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 60
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 30
- 239000002904 solvent Substances 0.000 claims description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- 230000001590 oxidative effect Effects 0.000 claims description 7
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- QEQBMZQFDDDTPN-UHFFFAOYSA-N (2-methylpropan-2-yl)oxy benzenecarboperoxoate Chemical compound CC(C)(C)OOOC(=O)C1=CC=CC=C1 QEQBMZQFDDDTPN-UHFFFAOYSA-N 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical group 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 3
- DGAPSMINGCVKLT-UHFFFAOYSA-N 2-tert-butylperoxyperoxy-2-methylpropane Chemical compound CC(C)(C)OOOOC(C)(C)C DGAPSMINGCVKLT-UHFFFAOYSA-N 0.000 claims description 3
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000012935 ammoniumperoxodisulfate Substances 0.000 claims description 3
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 238000010189 synthetic method Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- XMNIXWIUMCBBBL-UHFFFAOYSA-N 2-(2-phenylpropan-2-ylperoxy)propan-2-ylbenzene Chemical compound C=1C=CC=CC=1C(C)(C)OOC(C)(C)C1=CC=CC=C1 XMNIXWIUMCBBBL-UHFFFAOYSA-N 0.000 claims description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 claims description 2
- 235000019394 potassium persulphate Nutrition 0.000 claims description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 13
- 238000003786 synthesis reaction Methods 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 4
- 238000006555 catalytic reaction Methods 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 238000001308 synthesis method Methods 0.000 abstract description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 150000002576 ketones Chemical class 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 34
- 239000003480 eluent Substances 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000003208 petroleum Substances 0.000 description 9
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000004896 high resolution mass spectrometry Methods 0.000 description 7
- CHPVQLYVDDOWNT-UHFFFAOYSA-N 1-methylquinoxalin-2-one Chemical compound C1=CC=C2N=CC(=O)N(C)C2=C1 CHPVQLYVDDOWNT-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 5
- 239000011669 selenium Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 229910052723 transition metal Inorganic materials 0.000 description 4
- 150000003624 transition metals Chemical class 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960000956 coumarin Drugs 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- 150000004775 coumarins Chemical class 0.000 description 2
- 229950010033 ebselen Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- UFDULEKOJAEIRI-UHFFFAOYSA-N (2-acetyloxy-3-iodophenyl) acetate Chemical compound CC(=O)OC1=CC=CC(I)=C1OC(C)=O UFDULEKOJAEIRI-UHFFFAOYSA-N 0.000 description 1
- PEZNEXFPRSOYPL-UHFFFAOYSA-N (bis(trifluoroacetoxy)iodo)benzene Chemical compound FC(F)(F)C(=O)OI(OC(=O)C(F)(F)F)C1=CC=CC=C1 PEZNEXFPRSOYPL-UHFFFAOYSA-N 0.000 description 1
- UZIJSDLMSLIHJC-UHFFFAOYSA-N 1-propylquinoxalin-2-one Chemical compound C1=CC=C2N=CC(=O)N(CCC)C2=C1 UZIJSDLMSLIHJC-UHFFFAOYSA-N 0.000 description 1
- 238000004293 19F NMR spectroscopy Methods 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(II) bromide Substances [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical class C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000011941 photocatalyst Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 229940065287 selenium compound Drugs 0.000 description 1
- 150000003343 selenium compounds Chemical class 0.000 description 1
- 150000003346 selenoethers Chemical group 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N tert-butyl alcohol Substances CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- GJBRNHKUVLOCEB-UHFFFAOYSA-N tert-butyl benzenecarboperoxoate Chemical compound CC(C)(C)OOC(=O)C1=CC=CC=C1 GJBRNHKUVLOCEB-UHFFFAOYSA-N 0.000 description 1
- 201000009377 thymus cancer Diseases 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种7‑芳硒基喹喔啉酮衍生物(I)的制备方法,属有机合成化学技术领域。本发明以取代喹喔啉‑2(1H)‑酮衍生物与二芳基二硒醚为原料,Selectfluor氟试剂等为氧化剂,在无金属催化下,合成7‑芳硒基喹喔啉酮衍生物。本发明与已有的合成方法相比,具有以下的优点:(1)一步合成7‑芳硒基喹喔啉酮衍生物,原料及试剂廉价易得,成本低廉,有良好的应用前景;(2)仅对电子云密度比较低的喹喔啉酮7位碳进行芳硒基化,具有高的区域选择性;(3)反应条件温和,在空气条件下进行反应,产率高、操作方便等,有利于工业化生产。该类衍生物在医药、化工、材料等领域具有潜在的应用,本发明为7‑芳硒基喹喔啉酮衍生物的合成提供了一条新的途径。
Description
技术领域
本发明属于有机合成技术领域,具体涉及一种7-芳硒基喹喔啉酮衍生物的合成方法。
背景技术
硒具有抗癌、抗氧化、增强人体免疫、拮抗有害重金属、调节维生素的吸收、调节人体内蛋白质的合成以及增强生殖功能,同时也是肌肉中过氧化物酶的重要组成成分,已被广泛应用于医药、高分子材料、农药的合成,例如Ebselen (依布硒林)是日本第一制药和德国Nattermann公司开发的一种含有硒醚结构的新型抗炎药物分子。有机硒化合物广泛存在于天然产物以及具有生物活性的有机分子中,具有抗老年痴呆、防止帕金森病、胸腺癌、抗肿瘤等作用。此外,硒也是构成谷胱甘肽过氧化物酶的活性成分,作为自由基抑制剂,有效防止胰岛β细胞氧化破坏,促进糖份代谢、降低血糖和尿糖,改善糖尿病患者的症状,并且人体所需的半胱氨酸、蛋氨酸也存在含硒化合物。
几种常见的含不对称二芳基硒醚药物分子
基于含有不对称二芳基硒醚化合物具有的重要作用,人们对其合成开展了大量研究,尤其是对芳硒基芳香杂环化合物的合成,目前已经探索了多条合成方法:
2015年,Yin Shuangfeng等人(Zhu LZ,Qiu RH,Cao X,et al.Org.Lett., 2015,17,5528-5531.)以CuBr2为催化剂,8-酰胺基喹啉与二芳基二硒醚在180℃温度下反应24h得到5-芳硒基-8-酰胺基喹啉衍生物。该反应的缺点是使用过渡金属铜盐为催化剂,反应温度高,反应时间长等。
2017年,Liu Qiang等人(Zhang QB,Ban YL,Yuan,PF,et al.Green Chem., 2017,19,5559-5563.)报道了在蓝光照射条件下,光催化剂作用下,取代吲哚与二芳基二硒醚在空气中反应得到3-芳硒基吲哚衍生物。
2018年,Zhu Youquan等人(Zhu YQ,He JL,Niu YX,et al.J.Org.Chem., 2018,83,9958-9967.)报道了AgSbF6催化取代异喹啉酮衍生物与二芳基二硒醚化合物在110℃温度下合成4-芳硒基异喹啉酮衍生物,然而该反应需要过渡金属为催化剂且反应需要较高的温度,反应式如下:
2018年,Yang Daoshan等人(Yang DS,Li GQ,Xing,CY,et al.Org.Chem.Front.,2018,5,2974-2979.)报道了蓝光照射条件下,3-芳胺基香豆素衍生物与二芳基二硒醚在氧化剂(NH4)2S2O8作用下得到3-芳硒基-4-芳胺基香豆素衍生物,该反应的缺点是需要对香豆素的4位进行预官能团,底物适用范围较窄等,反应式如下:
2020年,Song Zengqiang等人(Song ZQ,Ding CH,Wang SL,et al.Chem.Commun.,2020,DOI:10.1039/c9cc09001k.)以二乙酰氧基碘苯(PIFA)为氧化剂,取代香豆素与二芳基二硒醚在室温下反应,得到3-芳硒基取代香豆素衍生物。
喹喔啉酮是药物中常见药效团,含有该结构母核的衍生物具有多种药理活性,被广泛用作抗肿瘤剂、抗菌剂、HIV-I逆转录酶抑制剂、抗凝血剂、降血糖剂等,是很多天然产物的结构骨架,在化学领域有着越来越重要的地位。通过对喹喔啉酮直接进行官能团化,所得衍生物也具有重要的生物活性,如肿瘤细胞增殖抑制剂、碟啶还原酶抑制剂、抗菌和抗肿瘤作用,并常用于药物、天然产物以及荧光材料等的合成中,显示出广阔的应用前景。目前,对喹喔啉酮进行官能团化主要是对喹喔啉酮的3位进行烷基化、芳基化、苄基化、磷酰化、酰化、烷氧化、氟烷基化、烷硫醚化等,在喹喔啉酮骨架上引入芳硒基官能团的研究方法报道较少,尤其是高选择性在喹喔啉酮的7位引入芳硒基官能团的合成方法至今未曾报道,仍存在继续进行研究和探索的必要,这也是本发明得以完成的基础和动力所在。
发明内容
本发明所要解决的第一个技术问题是高选择性合成7-芳硒基喹喔啉酮衍生物的合成路线问题。
本发明所要解决的第二个技术问题是7-芳硒基喹喔啉酮衍生物的制备过程简单高效,操作方便,条件温和,底物适用范围广,适合大规模工业化生产的问题。
为了解决上述技术问题,本发明提供如下技术方案:在有机溶剂中,以取代喹喔啉-2(1H)-酮衍生物为反应原料,二芳基二硒醚为硒基化试剂,在氧化剂作用下,通过喹喔啉-2(1H)-酮衍生物的C-H键直接芳硒基化得到7-芳硒基喹喔啉酮衍生物(I)。
上述的反应过程,可用下述的反应方程式表示:
其中,R1为C1-6的直链或支链烷基,苄基,苯环上的取代基是C1-6的直链或支链烷基、C1-6烷氧基、卤基、烯丙基或炔丙基的取代苄基;R2为苯基,单取代或双取代苯基且苯环上的取代基是C1-6的直链或支链烷基、C1-6烷氧基、卤基、乙酰氨基、乙酰氧基、二甲氨基、氰基、三氟甲基,2-噻吩基,2-呋喃基等杂环芳基。
本发明中所述氧化剂是70%过氧叔丁醇(TBHP)水溶液,二叔丁氧基过氧化物(DTBP),过氧化苯甲酸叔丁酯(TBPB),过二硫酸钾(K2S2O8),过二硫酸铵((NH4)2S2O8),Selectfluor氟试剂和过氧化二异丙基苯(DCP)等,优选 Selectfluor氟试剂。
本发明中所述的取代喹喔啉-2(1H)-酮衍生物、二芳基二硒基醚与氧化剂的投料物质的量之比为1:1-2:2-3,优选1:1:2.5。
本发明中所述的反应溶剂是乙腈、丙酮、二甲亚砜(DMSO)、1,2-二氯乙烷(DCE)、四氢呋喃(THF)、N,N-二甲基甲酰胺(DMA)、乙酸乙酯、水中的一种或多种,优选乙腈。
本发明的制备方法中,反应温度为60-100℃,反应温度优选80℃。
本发明的制备方法中,反应时间为2-8小时,优选4小时。
对反应后所得的混合物的提纯方法是:反应结束后,将反应液冷却后加入乙酸乙酯过滤,减压浓缩,将浓缩物通过柱色谱分离(其中硅胶为300-400 目),以石油醚和乙酸乙酯混合液为洗脱剂,收集洗脱液,浓缩后得到目标产物。
本发明所用试剂均市售可得。
本发明提供的7-芳硒基喹喔啉酮衍生物的制备方法具有如下有益效果: (1)反应的原子经济性高,符合绿色化学的要求;(2)反应具有高度的区域选择性,直接对喹喔啉酮的7位进行官能团化,得到7-芳硒基喹喔啉酮衍生物,合成效率高,达85%以上;(3)反应中无过渡金属催化,避免重金属在产品中的残留,降低资源浪费和环境污染;(4)原料价廉易得或者原料易于制备,反应条件温和,操作简便,底物的适用范围广,反应放大后反应效率高。
本发明以容易得到的取代喹喔啉酮为原料,以二芳基二硒醚为硒基化试剂,在空气氛围下,无过渡金属催化下,通过氧化物作用,高选择性反应得到式(I)所示结构的7-芳硒基喹喔啉酮衍生物。本发明为7-芳硒基喹喔啉酮衍生物的制备提供了一种绿色、高效且实用的新方法。
具体实施方式
下面通过具体的实施例对本发明进行详细说明,但这些例举性实施方式的用途和目的仅用来例举本发明,并非对本发明的实际保护范围构成任何形式的任何限定,更非将本发明的保护范围局限于此。
实施例1.R1=-Me,R2=-Ph时,1-甲基-7-苯硒基喹喔啉-2(1H)-酮衍生物的制备
在25mL圆底烧瓶中加入1-甲基喹喔啉-2(1H)-酮(0.2mmol,32.0mg)和二苯基二硒基醚(0.2mmol,62.8mg),再加入70%过氧叔丁醇水溶液(0.5mmol, 65.0mg),最后加入2mL1,2-二氯乙烷为溶剂。在80℃温度下反应5h;反应结束后,减压除去溶剂,向残液中加入10mL乙酸乙酯,用20mL饱和食盐水洗涤二次;有机层用无水Na2SO4干燥,减压浓缩后通过柱色谱(洗脱剂:乙酸乙酯/ 石油醚=1/5)分离提纯,得到无色固体0.054g,产率85.0%。
1H NMR(400MHz,CDCl3)δ:8.26(s,1H),7.95(d,JH-H=1.9Hz,1H),7.65(dd,JH-H=8.6Hz,JH-H=1.9Hz,1H),7.50-7.48(m,2H),7.30-7.27(m,3H),7.23(d,JH-H=8.7Hz, 1H),3.65(s,3H);13C NMR(100MHz,CDCl3)δ:154.7,150.7(CH),135.4(CH),134.3 (CH),133.8,133.3(CH),132.5,130.3,129.5(CH),127.8(CH),126.2,114.6(CH),28.8 (CH3),21.1(CH3);HR MS(ESI)m/z:calcd for C15H13N2OSe[M+H]+317.0188,found 317.0189.
实施例2.R1=-CH2CH2CH3,R2=-Ph时,1-正丙基-7-苯硒基喹喔啉-2(1H)-酮衍生物的制备
在25mL圆底烧瓶中加入1-丙基喹喔啉-2(1H)-酮(0.2mmol,37.6mg)和二苯基二硒基醚(0.2mmol,62.8mg),再加入二叔丁氧基过氧化物(0.5mmol, 73.0mg),最后加入2mLDMF为溶剂。在90℃温度下反应6h;反应结束后,减压除去溶剂,向残液中加入10mL乙酸乙酯,用20mL饱和食盐水洗涤二次;有机层用无水Na2SO4干燥,减压浓缩后通过柱色谱(洗脱剂:乙酸乙酯/石油醚= 1/6)分离提纯,得到无色固体0.060g,产率87.0%。
1H NMR(400MHz,CDCl3)δ:8.23(s,1H),7.94(d,JH-H=1.9Hz,1H),7.61(dd,JH-H=8.7Hz,JH-H=1.9Hz,1H),7.49-7.46(m,2H),7.26-7.24(m,3H),7.21(d,JH-H=8.7Hz, 1H),4.13(d,JH-H=7.8Hz,2H),1.80-1.71(m,2H),1.02(t,JH-H=7.8Hz,3H);13C NMR (100MHz,CDCl3)δ:154.5,150.7(CH),135.2(CH),134.5(CH),134.0,133.3(CH), 131.7,130.3,129.5(CH),127.8(CH),125.8,114.6(CH),43.5(CH2),20.6(CH2),11.3 (CH3);HR MS(ESI)m/z:calcd for C17H17N2OSe[M+H]+345.0501,found 345.0502.
实施例3.R1=-CH2COOC2H5,R2=-Ph时,1-乙氧酰乙基-7-苯硒基喹喔啉-2(1H)-酮衍生物的制备
在25mL圆底烧瓶中加入1-乙氧酰乙基喹喔啉-2(1H)-酮(0.2mmol,46.4 mg)和二苯基二硒基醚(0.2mmol,62.8mg),再加入Selectfluor氟试剂(0.5mmol, 177.0mg),最后加入1mL MeCN和1mL H2O为混合溶剂。在80℃温度下反应2 h;反应结束后,减压除去溶剂,向残液中加入10mL乙酸乙酯,用20mL饱和食盐水洗涤二次;有机层用无水Na2SO4干燥,减压浓缩后通过柱色谱(洗脱剂:乙酸乙酯/石油醚=1/3)分离提纯,得到无色固体0.070g,产率90.0%。
1H NMR(400MHz,CDCl3)δ:8.31(s,1H),7.97(d,JH-H=1.9Hz,1H),7.61(dd,JH-H=8.6Hz,JH-H=1.9Hz,1H),7.52-7.50(m,2H),7.31-7.29(m,3H),6.99(d,JH-H=8.7Hz, 1H),4.97(s,2H),4.24(q,JH-H=7.2Hz,2H),1.27(t,JH-H=7.2Hz,3H);13C NMR(100 MHz,CDCl3)δ:166.7,154.2,150.5(CH),135.3(CH),134.4(CH),133.8,133.5(CH), 131.6,130.1,129.6(CH),128.0(CH),126.7,114.1(CH),62.2(CH2),43.1(CH2),14.1 (CH3);HR MS(ESI)m/z:calcd for C18H17N2O3Se[M+H]+389.0399,found 389.0402.
实施例4.R1=-CH3,R2=对氟苯基时,1-甲基-7-(对氟苯硒基)喹喔啉-2(1H)-酮衍生物的制备
在25mL圆底烧瓶中加入1-甲基喹喔啉-2(1H)-酮(0.2mmol,32.0mg)和二对氟苯基二硒基醚(0.2mmol,70.0mg),再加入Selectfluor氟试剂(0.5mmol, 177.0mg),最后加入1mL MeCN和1mL H2O为混合溶剂。在80℃温度下反应3 h;反应结束后,减压除去溶剂,向残液中加入10mL乙酸乙酯,用20mL饱和食盐水洗涤二次;有机层用无水Na2SO4干燥,减压浓缩后通过柱色谱(洗脱剂:乙酸乙酯/石油醚=1/5)分离提纯,得到无色固体0.059g,产率88.0%。
1H NMR(400MHz,CDCl3)δ:8.27(s,1H),7.90(d,JH-H=1.6Hz,1H),7.61(dd,JH-H=8.7Hz,JH-H=1.7Hz,1H),7.54-7.51(m,2H),7.23(d,JH-H=8.7Hz,1H),7.01(t,JH-H=8.7Hz,2H),3.66(s,3H);13C NMR(100MHz,CDCl3)δ:162.8(d,JF-C=247.1Hz),154.7, 150.8(CH),136.0(d,JF-C=8.0Hz,CH),134.7(CH),133.8(CH),133.7,132.5,126.6, 124.6,116.8(d,JF-C=21.6Hz,CH),114.6(CH),28.8(CH3);19F NMR(376MHz,CDCl3) δ:-113.0;HRMS(ESI)m/z:calcd for C15H12FN2OSe[M+H]+335.0093,found 335.0091.
实施例5.R1=-CH3,R2=对溴苯基时,1-甲基-7-(对溴苯硒基)喹喔啉-2(1H)-酮衍生物的制备
在25mL圆底烧瓶中加入1-甲基喹喔啉-2(1H)-酮(0.2mmol,32.0mg)和二对溴苯基二硒基醚(0.2mmol,94.0mg),再加入过二硫酸铵(0.5mmol,114.0 mg),最后加入2mL MeCN为溶剂。在70℃温度下反应6h;反应结束后,减压除去溶剂,向残液中加入10mL乙酸乙酯,用20mL饱和食盐水洗涤二次;有机层用无水Na2SO4干燥,减压浓缩后通过柱色谱(洗脱剂:乙酸乙酯/石油醚=1/5) 分离提纯,得到无色固体0.068g,产率86%。
1H NMR(400MHz,CDCl3)δ:8.27(s,1H),7.96(d,JH-H=2.0Hz,1H),7.65(dd,JH-H=8.7Hz,JH-H=2.0Hz,1H),7.38(d,JH-H=8.5Hz,2H),7.32(d,JH-H=8.5Hz,2H),7.25 (d,JH-H=8.7Hz,1H),3.65(s,3H);13C NMR(100MHz,CDCl3)δ:154.7,150.9(CH), 135.6(CH),134.8(CH),134.5(CH),133.8,132.8(CH),129.6,125.3,122.1,114.8(CH), 28.8(CH3);HR MS(ESI)m/z:calcd for C15H12BrN2OSe[M+H]+394.9293,found 394.9294.
实施例6.R1=-CH3,R2=对氰苯基时,1-甲基-7-(对氰苯硒基)喹喔啉-2(1H)-酮衍生物的制备
在25mL圆底烧瓶中加入1-甲基喹喔啉-2(1H)-酮(0.2mmol,32.0mg)和二对氰苯基二硒基醚(0.2mmol,72.8mg),再加入过二硫酸钾(0.5mmol,135.0 mg),最后加入2mL丙酮为溶剂。在60℃温度下反应8h;反应结束后,减压除去溶剂,向残液中加入10mL乙酸乙酯,用20mL饱和食盐水洗涤二次;有机层用无水Na2SO4干燥,减压浓缩后通过柱色谱(洗脱剂:乙酸乙酯/石油醚=1/5) 分离提纯,得到无色固体0.060g,产率89%。
1H NMR(400MHz,CDCl3)δ:8.32(s,1H),8.14(d,JH-H=1.9Hz,1H),7.78(dd,JH-H=8.6Hz,JH-H=1.9Hz,1H),7.48(d,JH-H=8.4Hz,2H),7.38-7.34(m,3H),3.70(s,3H);13C NMR(100MHz,CDCl3)δ:154.7,151.2(CH),139.9,137.7(CH),137.4(CH),133.9, 132.5(CH),130.5(CH),122.1,118.5,115.3(CH),110.2,28.9(CH3);HR MS(ESI)m/z: calcd forC16H12N3OSe[M+H]+342.0140,found 342.0143.
在25mL圆底烧瓶中加入1-甲基喹喔啉-2(1H)-酮(0.2mmol,32.0mg)和二(2-噻吩基)二硒基醚(0.2mmol,65.2mg),再加入Selectfluor氟试剂(0.5mmol, 177.0mg),最后加入1mL MeCN和1mL H2O为混合溶剂。在80℃温度下反应4 h;反应结束后,减压除去溶剂,向残液中加入10mL乙酸乙酯,用20mL饱和食盐水洗涤二次;有机层用无水Na2SO4干燥,减压浓缩后通过柱色谱(洗脱剂:乙酸乙酯/石油醚=1/4)分离提纯,得到无色固体0.055g,产率85.0%。
1H NMR(400MHz,CDCl3)δ:8.25(s,1H),7.92(d,JH-H=1.9Hz,1H),7.65(dd,JH-H=8.6Hz,JH-H=1.9Hz,1H),7.20(d,JH-H=8.7Hz,1H),7.42-7.39(m,2H),7.15(t,JH-H=4.5Hz,1H),3.60(s,3H);13C NMR(100MHz,CDCl3)δ:153.0(C=O),152.7,141.5, 136.2(CH),136.0(CH),133.1,132.3(CH),131.7,130.0(CH),127.4(CH),124.4(CH), 114.2(CH),28.0(CH3).HR MS(ESI)m/z:calcd for C13H11N2OSSe[M+H]+322.9752, found322.9753.
实施例8.R1=-CH3,R2=对甲苯基时,1-甲基-7-(4-甲基苯硒基)喹喔啉-2(1H)-酮衍生物的制备
在25mL圆底烧瓶中加入1-甲基喹喔啉-2(1H)-酮(0.2mmol,32.0mg)和二对甲苯基二硒基醚(0.2mmol,68.4mg),再加入过氧苯甲酸叔丁酯(0.5mmol, 97.0mg),最后加入2mL四氢呋喃为溶剂。在75℃温度下反应6h;反应结束后,减压除去溶剂,向残液中加入10mL乙酸乙酯,用20mL饱和食盐水洗涤二次;有机层用无水Na2SO4干燥,减压浓缩后通过柱色谱(洗脱剂:乙酸乙酯/石油醚=1/5)分离提纯,得到无色固体0.058g,产率88%。
1H NMR(400 MHz,CDCl3)δ:8.26(s,1H),7.71(d,JH-H=2.2 Hz,1H),7.49(dd,JH-H=8.8Hz,JH-H=2.2 Hz,1H),7.32(d,JH-H=8.1 Hz,2H),7.24(d,JH-H=8.8 Hz,1H),7.15 (d,JH-H=8.1 Hz,2H),3.65(s,3H),2.35(s,3H);13C NMR(100 MHz,CDCl3)δ:154.7, 150.7(CH),138.3,133.7,133.1,132.6(CH),132.4(CH),131.8,130.8(CH),130.4(CH), 130.3,114.4(CH),28.8(CH3),21.1(CH3);HR MS(ESI)m/z:calcd for C16H15N2OSe[M+ H]+331.0350,found 331.0352。
Claims (5)
2.根据权利要求1所述的氧化剂是70%过氧叔丁醇(TBHP)水溶液,二叔丁氧基过氧化物(DTBP),过氧化苯甲酸叔丁酯(TBPB),过二硫酸钾(K2S2O8),过二硫酸铵((NH4)2S2O8),Selectfluor氟试剂和过氧化二异丙基苯(DCP)等。
3.根据权利要求1所述的7-芳硒基喹喔啉酮衍生物的合成方法,其特征在于,所述的取代喹喔啉-2(1H)-酮衍生物、二芳基二硒基醚与氧化剂的投料物质的量之比为1:1-2:2-3。
4.根据权利要求1所述的溶剂是乙腈、丙酮、二甲亚砜(DMSO)、1,2-二氯乙烷(DCE)、四氢呋喃(THF)、N,N-二甲基甲酰胺(DMA)、乙酸乙酯、水中的一种或多种。
5.根据权利要求1所述的7-芳硒基喹喔啉酮衍生物的制备方法,其特征在于,反应温度为60-100℃,反应时间为2-8小时。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010575297.XA CN111689911A (zh) | 2020-06-22 | 2020-06-22 | 一种区域选择性合成7-芳硒基喹喔啉酮衍生物的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010575297.XA CN111689911A (zh) | 2020-06-22 | 2020-06-22 | 一种区域选择性合成7-芳硒基喹喔啉酮衍生物的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111689911A true CN111689911A (zh) | 2020-09-22 |
Family
ID=72482383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010575297.XA Pending CN111689911A (zh) | 2020-06-22 | 2020-06-22 | 一种区域选择性合成7-芳硒基喹喔啉酮衍生物的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111689911A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112961105A (zh) * | 2021-01-28 | 2021-06-15 | 绍兴文理学院 | 一种含氮杂环化合物的烷基化方法 |
CN113105397A (zh) * | 2021-02-25 | 2021-07-13 | 浙江农林大学暨阳学院 | 一种锌催化制备2-苯亚硒砜基喹喔啉类化合物的方法 |
-
2020
- 2020-06-22 CN CN202010575297.XA patent/CN111689911A/zh active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112961105A (zh) * | 2021-01-28 | 2021-06-15 | 绍兴文理学院 | 一种含氮杂环化合物的烷基化方法 |
CN112961105B (zh) * | 2021-01-28 | 2022-10-18 | 绍兴文理学院 | 一种含氮杂环化合物的烷基化方法 |
CN113105397A (zh) * | 2021-02-25 | 2021-07-13 | 浙江农林大学暨阳学院 | 一种锌催化制备2-苯亚硒砜基喹喔啉类化合物的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107056727B (zh) | 一种2-芳基-5-芳硒基-1,3,4-噁二唑化合物及制备方法 | |
CN108033922B (zh) | 一种3-酰基喹喔啉酮衍生物的制备方法 | |
CN110204486B (zh) | 一种喹啉衍生物的合成方法 | |
CN111910209B (zh) | 一种3-芳硒基喹啉酮化合物的电化学合成方法 | |
CN111689911A (zh) | 一种区域选择性合成7-芳硒基喹喔啉酮衍生物的方法 | |
CN110386885B (zh) | 一种可见光促进β-羰基砜化合物的制备方法 | |
CN105175328A (zh) | 一种利用芳香胺、芳香醛、酮合成喹啉衍生物的方法 | |
CN113620891B (zh) | 一种可控催化制备喹喔啉-2-酮类衍生物的方法 | |
CN112500339B (zh) | 一种8-酰基喹啉衍生物的合成方法 | |
CN103739536A (zh) | 一种二芳基双硒醚化合物的合成方法 | |
CN109053510A (zh) | 一种可见光催化的三氟甲基取代的硫烯酮衍生物的合成方法 | |
CN112442008A (zh) | 一种温度调控单质硫与活泼内炔制备1,4-二噻烯和噻吩类化合物的方法及其转化反应 | |
CN109651271B (zh) | 一种3-叔丁基-n-甲基喹喔啉-2(1h)-酮化合物的合成方法 | |
CN110655506B (zh) | 一种替加氟的制备方法 | |
CN115572300A (zh) | 一种磺酰胺基取代多环喹唑啉酮化合物的合成方法 | |
CN111362795B (zh) | 一类取代丁酸酯类衍生物的制备方法 | |
CN111518021B (zh) | 一种利用混合苯乙烯衍生物与n,n-二甲基甲酰胺构建3,5-二取代吡啶的方法 | |
CN110627823B (zh) | 一种催化芳基胺发生脱氨基硼酸酯化或卤化的方法 | |
CN113444088A (zh) | 一种苯并[4,5]咪唑并[2,1-a]异喹啉-6(5H)-酮及其衍生物、制备方法 | |
CN113173909A (zh) | 一种含硒/碲杂环类化合物及其制备方法和转化方法 | |
CN114920684B (zh) | 含硒苯甲酰胺类化合物及其合成方法与应用 | |
Milne et al. | A Synthesis of α-lithiated enol ethers from α-arenesulfinyl enol ethers: Ni (0)-and Pd (0)-catalysed coupling of enol triflates and phosphates derived from lactones with sodium arenethiolates gives α-arenesulfanyl enol ethers | |
CN111116552B (zh) | 一种喹唑啉酮类化合物及其制备方法 | |
CN115109009B (zh) | 一种2-磺酰基苯并噻唑类化合物的合成方法 | |
CN112028841B (zh) | 一种3-芳基-n-甲基喹喔啉-2(1h)-酮化合物的光催化合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200922 |
|
WD01 | Invention patent application deemed withdrawn after publication |